![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology firm with operations within the United States and China targeted on early most cancers screening and detection, at this time introduced adjustments to its board composition and administration group.
Mr. Haohan Xu has been appointed as a director of the board of administrators (the “Board”), Co-Chairperson of the Board and Co-Chief Executive Officer of the Company. Mr. Xu is the Chief Executive Officer of Apifiny Group Inc., a digital asset buying and selling infrastructure supplier based mostly in New York, United States and has been actively engaged within the fintech business with previous directorship and senior government positions held at fintech corporations together with Mercurity Fintech Holding Inc. (Nasdaq: MFH).
Ms. Xiaoyu Li has been appointed as a director of the Board and as Chief Financial Officer of the Company. Ms. Li has intensive expertise in investor relations and funding. From May 2018 to August 2021, Ms. Li served as a director of Mercurity Fintech Holding Inc. (Nasdaq: MFH), the place Ms. Li beforehand labored on the investor relations division from 2012 to 2013.
Mr. Tianruo (Robert) Pu has been appointed as a director of the Board, chairperson of the audit committee and member of the compensation committee in addition to nominating and company governance committee. Mr. Pu at the moment serves as an impartial director of Autohome Inc. (NYSE: ATHM; HKSE: 2518), One Connect Financial Technology (NYSE: OCFT) and 3SBio Inc. (HKSE: 1530).
Mr. Zhigang (Frank) Zhao has been appointed as a director of the Board, chairperson of the compensation committee and member of the audit committee in addition to nominating and company governance committee. Mr. Zhao has over 20 years of expertise in monetary and accounting administration with auditing corporations and public corporations.
Mr. Honggang (Harvey) Tian has been appointed as a director of the Board, chairperson of the nominating and company governance committee and member of the audit committee in addition to compensation committee. Mr. Tian is an skilled funding skilled, with explicit focus in Internet and high-tech industries.
In relation to the above appointments, every of Mr. Chris Chang Yu, Jinqiu Tang, Xing Pu, Ren Luo, Jianhua Shao and Guo Feng will resign as a director and/or officer of the Company. These adjustments are anticipated to change into efficient in early October after the completion of customary onboarding processes, together with required filings with The Registry of Corporate Affairs within the British Virgin Islands.
Under the brand new construction, Dr. Chris Chang Yu will proceed to handle Company’s most cancers screening know-how improvement and develop its business.
“We are delighted to welcome Mr. Haohan Xu, Ms. Xiaoyu Li, Mr. Tianruo Pu, Mr. Zhigang Zhao and Mr. Honggang Tian to the Board and management team,” mentioned Dr. Chris Yu, Co-Chairman of the Board and Co-Chief Executive Officer of the Company. “We believe their experience and expertise will provide significant value to AnPac Bio as we continue to explore growth opportunities in our early cancer screening and detection business and explore strategic alternatives to further unlock value for shareholders. On behalf of the Board, I would also like to express my sincere gratitude to the departing directors for their incredible contribution to the Company during their tenure on the Board and wish them well for the future.”
About AnPac Bio
AnPac Bio is a biotechnology firm targeted on early most cancers screening and detection, with 155 issued patents as of March 31, 2022. With two licensed medical laboratories in China and one CLIA and CAP accredited medical laboratory within the United States, AnPac Bio performs a set of most cancers screening and detection checks, together with CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics checks. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multi-cancer screening and detection check pattern quantity (accumulative to January 2021). AnPac Bio’s CDA know-how platform has been proven in retrospective validation research to have the ability to detect the danger of over 20 totally different most cancers sorts with excessive sensitivity and specificity.
For investor and media inquiries, please contact:
Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: [email protected]
Inventor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: [email protected]
Safe Harbor Statement
This announcement accommodates forward-looking statements throughout the which means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made below the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are referring to the Company’s future monetary and working efficiency. The Company has tried to determine forward-looking statements by terminologies together with “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. These statements are based mostly on present expectations, assumptions and uncertainties involving judgments about, amongst different issues, future financial, aggressive and market circumstances and future business selections, all of that are troublesome or unimaginable to foretell precisely and lots of that are past the Company’s management. These statements additionally contain identified and unknown dangers, uncertainties and different components which will trigger the Company’s precise outcomes to be materially totally different from these expressed or implied by any forward-looking assertion. Known and unknown dangers, uncertainties and different components embrace, however should not restricted to, our skill to adjust to Nasdaq Listing Rules, the implementation of our business mannequin and development methods; tendencies and competitors within the most cancers screening and detection market; our expectations relating to demand for and market acceptance of our most cancers screening and detection checks and our skill to increase our buyer base; our skill to acquire and keep mental property protections for our CDA know-how and our continued analysis and improvement to maintain tempo with know-how developments; our skill to acquire and keep regulatory approvals from the NMPA, the FDA and the related U.S. states and have our laboratories licensed or accredited by authorities together with the CLIA; our future business improvement, monetary situation and outcomes of operations and our skill to acquire financing cost-effectively; potential adjustments of presidency laws; common financial and business circumstances in China and elsewhere; our skill to rent and keep key personnel; our relationship with our main business companions and clients; and the length of the coronavirus outbreaks and their potential adversarial influence on the financial circumstances and monetary markets and our business and monetary efficiency, reminiscent of ensuing from decreased industrial actions attributable to quarantines and journey restrictions instituted by China, the U.S. and many different nations around the globe to include the unfold of the virus. Additionally, all forward-looking statements are topic to the “Risk Factors” detailed every now and then within the Company’s most up-to-date Annual Report on Form 20-F and different filings with the U.S. Securities and Exchange Commission. Because of those and different dangers, uncertainties and assumptions, undue reliance shouldn’t be positioned on these forward-looking statements. In addition, these statements converse solely as of the date of this press launch and, besides as could also be required by legislation, the Company undertakes no obligation to revise or replace publicly any forward-looking statements for any purpose.
